MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

21.14 3.48

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.29

Максимум

21.53

Ключови измерители
By Trading Economics
Приходи	9.2M -16M
Продажби	16M 82M
Марж на печалбата	-19.491
Служители	342
EBITDA	6.7M -12M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+10.79% upside

Дивиденти
By Dow Jones
Следващи печалби	28.10.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	639M 2.4B
Предишно отваряне	17.66
Предишно затваряне	21.14

Настроения в новините

By Acuity

24%

76%

28 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.10.2025 г., 20:45 ч. UTC

Печалби

Costco Wholesale Sales Climb in September, Early October

8.10.2025 г., 20:12 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

TaskUs Shares Fall After Holders Reject Take-Private Deal

8.10.2025 г., 16:39 ч. UTC

Значими двигатели на пазара

Mining Shares Rise as Gold Prices Soar

8.10.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen -- Market Talk

8.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Falls on Possible Profit-Taking -- Market Talk

8.10.2025 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics to Finance Acquisition Using Internal Funds

8.10.2025 г., 23:17 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8.10.2025 г., 23:16 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8.10.2025 г., 21:54 ч. UTC

Пазарно говорене

Печалби

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8.10.2025 г., 21:30 ч. UTC

Пазарно говорене

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8.10.2025 г., 21:26 ч. UTC

Пазарно говорене

Печалби

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.10.2025 г., 19:15 ч. UTC

Пазарно говорене

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8.10.2025 г., 19:01 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8.10.2025 г., 18:47 ч. UTC

Пазарно говорене

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

TaskUs Will Remain a Publicly Traded Co >TASK

8.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8.10.2025 г., 18:07 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Edging Up in September -- Market Talk

8.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Energy & Utilities Roundup: Market Talk

8.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.10.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.10.2025 г., 15:57 ч. UTC

Пазарно говорене

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8.10.2025 г., 15:56 ч. UTC

Пазарно говорене

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8.10.2025 г., 15:53 ч. UTC

Пазарно говорене

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8.10.2025 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8.10.2025 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8.10.2025 г., 15:43 ч. UTC

Придобивния, сливания и поглъщания

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8.10.2025 г., 15:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

10.79% нагоре

12-месечна прогноза

Среден 22.79 USD 10.79%

Висок 29 USD

Нисък 14.29 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

28 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.